全文获取类型
收费全文 | 7852篇 |
免费 | 414篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 103篇 |
妇产科学 | 57篇 |
基础医学 | 1242篇 |
口腔科学 | 103篇 |
临床医学 | 483篇 |
内科学 | 2040篇 |
皮肤病学 | 121篇 |
神经病学 | 583篇 |
特种医学 | 302篇 |
外科学 | 1425篇 |
综合类 | 41篇 |
一般理论 | 3篇 |
预防医学 | 214篇 |
眼科学 | 104篇 |
药学 | 450篇 |
中国医学 | 26篇 |
肿瘤学 | 957篇 |
出版年
2023年 | 76篇 |
2022年 | 123篇 |
2021年 | 267篇 |
2020年 | 158篇 |
2019年 | 218篇 |
2018年 | 270篇 |
2017年 | 150篇 |
2016年 | 200篇 |
2015年 | 190篇 |
2014年 | 247篇 |
2013年 | 286篇 |
2012年 | 489篇 |
2011年 | 550篇 |
2010年 | 304篇 |
2009年 | 244篇 |
2008年 | 432篇 |
2007年 | 453篇 |
2006年 | 464篇 |
2005年 | 421篇 |
2004年 | 409篇 |
2003年 | 343篇 |
2002年 | 342篇 |
2001年 | 162篇 |
2000年 | 166篇 |
1999年 | 133篇 |
1998年 | 74篇 |
1997年 | 56篇 |
1996年 | 57篇 |
1995年 | 51篇 |
1994年 | 63篇 |
1993年 | 44篇 |
1992年 | 97篇 |
1991年 | 83篇 |
1990年 | 68篇 |
1989年 | 79篇 |
1988年 | 73篇 |
1987年 | 80篇 |
1986年 | 49篇 |
1985年 | 51篇 |
1984年 | 39篇 |
1983年 | 30篇 |
1982年 | 20篇 |
1981年 | 11篇 |
1980年 | 15篇 |
1979年 | 36篇 |
1978年 | 13篇 |
1977年 | 16篇 |
1974年 | 16篇 |
1972年 | 10篇 |
1970年 | 15篇 |
排序方式: 共有8307条查询结果,搜索用时 15 毫秒
1.
2.
Koji Tokunaga Akihiro Furuta Hiroyoshi Isoda Shinji Uemoto Kaori Togashi 《Diagnostic and interventional radiology (Ankara, Turkey)》2021,27(1):65
PURPOSEWe aimed to evaluate mid- to long-term results of endovascular treatment for portal vein thrombosis (PVT) after living-donor liver transplantation (LDLT).METHODSThirty cases (14 males, 16 females; age range, 0.67–65 years) who underwent endovascular treatment including thrombolysis, angioplasty, stent placement, and/or collateral embolization for PVT after LDLT from 2001 to 2017 were retrospectively reviewed. Clinical and procedural data were collected and analyzed regarding the patency of the PVT site at the last follow-up date (PVT-free persistency) using Log-rank test. Results were considered statistically significant at p < 0.05.RESULTSMedian follow-up was 120 months. The technical success rate was 80% (n=24). Patency rates at 1 week and 1, 3, 6, 12, 36, and 60 months were 73%, 59%, 55%, 51%, 51%, 51%, and 51% for primary patency and 80%, 70%, 66%, 66%, 66%, 61%, and 61% for assisted patency after secondary endovascular treatment. PVT-free persistency rates regarding the subgroups were as follows: children under 12 years vs. adults, 50% vs. 68% (p = 0.42); acute vs. nonacute, 76% vs. 46% (p = 0.10); localized vs. extensive, 90% vs. 50% (p = 0.035); transileocolic approach vs. percutaneous-transhepatic approach, 71% vs. 54% (p = 0.39); and thrombolysis-based treatment vs. non-thrombolysis-based treatment, 71% vs. 44% (p = 0.12), respectively. Among technically successful cases, PVT-free persistency rate was 94% for those with hepatopetal flow in the peripheral portal vein vs. 17% for those without hepatopetal flow (p < 0.001). The only major complication occurring was pleural hemorrhage (n=1). Minor complications (i.e., fever) occurred in 18 patients (60%).CONCLUSIONIn conclusion, mid- to long-term portal patency following endovascular treatment was approximately 50%–60% in PVT patients after LDLT. PVT site patency over three months after the first endovascular treatment, localized PVT, and hepatopetal flow in the peripheral portal vein were identified as key prognostic factors for mid- to long-term portal patency.Portal vein thrombosis (PVT) is a vascular complication of living-donor liver transplantation (LDLT), with an estimated incidence of up to 4% (1, 2). The risk of vascular complications, including PVT, is higher in LDLT compared with conventional deceased-donor liver transplantation, because of the smaller vessels, insufficient vessel length for reconstruction, neointimal proliferation, and higher risk of twisting and kinking of the vascular pedicle (3) due to smaller graft size than in deceased-donor liver transplantation. PVT after LDLT can lead to graft failure and the need for retransplantation or death (2), making immediate treatment crucial.Endovascular-based treatment is one option for treating PVT. The utility of target-focused thrombolysis, balloon angioplasty, and stent placement to restore portal flow has been reported previously (4–10). However, the efficacy of endovascular treatment after LDLT has only been presented in some case reports (11, 12) and the mid- to long-term outcomes remain unclear.The purpose of this study was to evaluate the technical success, feasibility, and mid- to long-term results of endovascular treatment for PVT after LDLT in our institution. 相似文献
3.
4.
Intake of arsenic from water, food composites and excretion through urine, hair from a studied population in West Bengal, India. 总被引:4,自引:0,他引:4
To evaluate the main intake source of arsenic by the villagers from arsenic-affected families in Jalangi and Domkol blocks in Mushidabad district, West Bengal-India, we determined the concentrations of arsenic in tube-well water and in food composites, mainly including vegetables and cereals collected from the surveyed families which were cultivated in that region. The daily dietary intakes of arsenic by the villagers were estimated and the excretions of arsenic through urine and hair were determined. The arsenic concentrations in hair and urine of the studied population living in mild (2.78 microg/L), moderate (30.7 microg/L) and high (118 microg/L) arsenic-affected families were 133, 1,391 and 4,713 microg/kg and 43.1, 244 and 336 microg/L, respectively. The linear regressions show good correlations between arsenic concentrations in water vs hair (r(2)=0.928, p<0.001) and water vs urine (r(2)=0.464, p<0.01). Approximately 29.4%, 58.1% and 62.1% of adult population from mild, moderate and high arsenic-affected families were suffering from arsenical skin manifestations. The mean arsenic concentrations of food composites (vegetables and cereals) in high arsenic-affected families are not significantly different from mild arsenic-affected families. The daily dietary intakes of arsenic from water and food composites of the studied population, living in high, moderate and mild arsenic-affected families were 568, 228 and 137 microg, respectively. The linear regressions show good correlations between arsenic concentrations in hair vs daily dietary intake (r(2)=0.452, p<0.001) and urine vs daily dietary intake (r(2)=0.134, p<0.001). The water for drinking contributed 6.07%, 26.7% and 58.1% of total arsenic in our study from mild, moderate and high arsenic-affected families. The result suggested that the contaminated water from high arsenic-affected families should be the main source for intake of arsenic. On contrary, the contribution of arsenic-contaminated food composites from mild and moderate arsenic-affected families might be the main source for intake of arsenic. The Food and Agriculture Organization/World Health Organization (FAO/WHO) provisional tolerable weekly intake (PTWI) values of arsenic in our study were 3.32, 5.75 and 12.9 microg/kg body weight/day from mild, moderate and high arsenic-affected families, respectively, which is higher than the recommended PTWI value of arsenic (2.1 microg/kg body weight/day). 相似文献
5.
6.
7.
8.
Hisato Takagi Toshiyuki Tanabashi Norikazu Kawai Takuya Umemoto 《European journal of cardio-thoracic surgery》2007,32(2):400; author reply 400-400; author reply 401
9.
10.